NCTR Research Highlights
2013 Global Summit on Regulatory Science (GSRS13)
Dates: September 11-12, 2013
Location: Little Rock, Arkansas
Current Highlight from May 17, 2013
KRAS Mutant Subpopulations and Implications for Cancer Therapeutics
NCTR scientists published an invited review in Discovery Medicine (2013, 15:259-267) that discusses the implications of KRAS mutant subpopulations in colon tumors on the efficacy of personalized cancer treatments. The authors summarize evidence that most colon tumors carry KRAS mutations; and few, if any, colon tumors are truly KRAS wild-type. The use of monotherapies that target KRAS wild-type tumor cells creates an opportunity for the outgrowth of KRAS mutant subpopulations, which can lead to acquired resistance to treatment and relapse. Thus, combination therapeutics that target KRAS mutant cells may provide a more effective treatment of advanced colorectal cancer.
For additional information, please contact Barbara Parsons, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR, or Meagan Myers, Ph.D., Staff Fellow, Division of Genetic and Molecular Toxicology, FDA/NCTR.